OpGen is uniquely positioned to address the rising antibiotic resistance crisis and is harnessing the power of informatics and genomic analysis to provide complete solutions to protect patients in hospitals and healthcare networks.
Using our large and ever-growing Acuitas Lighthouse® Database of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases.
Today, through our CLIA-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. Our FDA-cleared, IVD products rapidly identify pathogens in positive blood cultures.
Rapid Antibiotic Resistance Surveillance
Acuitas® Surveillance Program
High Resolution Microbial Sequencing
Acuitas® Whole Genome Sequence Analysis
Rapid Pathogen Identification in Blood Stream Infections
AdvanDx® FISH Tests
About Antibiotic Resistance
Every year, more than two million people in the U.S. become ill from antibiotic-resistant bacteria, and 23,000 of them die. The U.S. Centers for Disease Control and Prevention (CDC) estimates that antibiotic resistance causes $20 billion in excess direct healthcare costs and the report “Antimicrobial Resistance: Taking a Crisis for the Health and Wealth of Nations” (Review on Antimicrobial Resistance) predicts that antimicrobial resistance will be a bigger killer than cancer in the year 2050 with a projected 10 million deaths annually. Multi-drug resistant organisms (MDROs), or superbugs, are a global healthcare issue and the CDC and other public health organizations have called for new molecular technologies for MDRO testing that can detect more quickly and accurately, improving infection control programs and providing hospitals with faster, more targeted antibiotic response and stewardship programs.